ME02705B - Inženjerisana anti-il-23 antitela - Google Patents

Inženjerisana anti-il-23 antitela

Info

Publication number
ME02705B
ME02705B MEP-2017-73A MEP7317A ME02705B ME 02705 B ME02705 B ME 02705B ME P7317 A MEP7317 A ME P7317A ME 02705 B ME02705 B ME 02705B
Authority
ME
Montenegro
Prior art keywords
antibody
binding fragment
antigen
residues
seq
Prior art date
Application number
MEP-2017-73A
Other languages
German (de)
English (en)
French (fr)
Inventor
Leonard G Presta
Peter Orth
Brian M Beyer
Yan-Hui Liu
Richard N Ingram
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37685722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02705(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of ME02705B publication Critical patent/ME02705B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (17)

1. Antitelo, ili njegov antigen-vezujući fragment, naznačen time, što se vezuje za humani IL-23p19 na epitopu koji sadrži rezidue 82-95 i rezidue 133-140 SEQ ID NO: 29.
2. Antitelo, ili njegov antigen-vezujući fragment, iz zahteva 1, naznačen time, što se vezuje za epitop koji sadrži rezidue E82, G86, S87, D88, T91, G92, E93, P94, S95, H106, P133, S134, Q135, P136, W137, R139 i L140 SEQ ID NO: 29.
3. Antitelo, ili njegov antigen-vezujući fragment, iz zahteva 1, naznačen time, što antitelo sadrži: CDRL1 koji se sastoji od rezidua 43-53 SEQ ID NO: 4; CDRL2 koji se sastoji od rezidua 69-75 SEQ ID NO: 4; CDRL3 koji se sastoji od rezidua 108-116 SEQ ID NO: 4; CDRH1 koji se sastoji od rezidua 45-54 SEQ ID NO: 3; CDRH2 koji se sastoji od rezidua 69-85 SEQ ID NO: 3; i CDRH3 koji se sastoji od rezidua 118-123 SEQ ID NO: 3.
4. Antitelo, ili njegov antigen-vezujući fragment, iz zahteva 3, naznačen time, što: varijabilni region lakog lanca antitela, ili njegovog vezujućeg fragmenta, sadrži sekvencu rezidua 20-129 SEQ ID NO: 4, ili njenu varijantu; i varijabilni region teškog lanca antitela, ili njegovog vezujućeg fragmenta, sadrži sekvencu rezidua 20-134 SEQ ID NO: 3, ili njenu varijantu; pri čemu varijanta sadrži do 20 konzervativno modifikovanih aminokiselinskih supstitucija.
5. Antitelo, ili njegov antigen-vezujući fragment, iz zahteva 4, naznačen time, što je vezujuće jedinjenje antitelo, ili njegov vezujući fragment, koji uključuje: varijabilni region lakog lanca koji sadrži rezidue 20-129 SEQ ID NO: 4; i varijabilni region teškog lanca koji sadrži rezidue 20-134 SEQ ID NO: 3.
6. Antitelo ili njegov antigen-vezujući fragment iz zahteva 3, naznačen time, što blokira aktivnost posredovanu IL-23.
7. Izolovana nukleinska kiselina, naznačena time, što kodira varijabilni region lakog lanca i varijabilni region teškog lanca antitela, ili njegovog antigen- vezujućeg fragmenta, iz zahteva 4.
8. Ekspresioni vektor, naznačen time, što sadrži nukleinsku kiselinu iz zahteva 7 operabilno povezanu sa kontrolnim sekvencama koje prepoznaje ćelija-domaćin, kada se ćelija-domaćin transfektuje vektorom.
9. Ćelija-domaćin, naznačena time, što sadrži ekspresioni vektor iz zahteva 8.
10. Metod proizvodnje polipeptida, naznačen time, što uključuje: kultivisanje ćelije-domaćina iz zahteva 9 u kultivacionom medijumu pod uslovima pod kojima se eksprimira sekvenca nukleinske kiseline, čime se proizvode polipeptidi koji sadrže varijabilne regione lakog i teškog lanca; i sakupljanje polipeptida iz ćelije-domaćina ili kultivacionog medijuma.
11. Antitelo, ili njegov antigen-vezujući fragment, iz zahteva 2, naznačen time, što sadrži konstantni region humanog γ1 teškog lanca.
12. Antitelo ili njegov antigen-vezujući fragment iz zahteva 2, naznačen time, što sadrži konstantni region humanog γ4 teškog lanca.
13. Antitelo, ili njegov antigen-vezujući fragment, iz zahteva 1, naznačen time, što se fragment antitela bira iz grupe koja se sastoji od Fab, Fab’, Fab’-SH, Fv, scFv, F(ab’)2 i dijatela.
14. Smeša, naznačena time, što sadrži antitelo, ili njegov antigen-vezujući fragment, iz zahteva 4 u kombinaciji sa farmaceutski prihvatljivim nosačem ili razblaživačem.
15. Smeša iz zahteva 14, naznačena time, što sadrži još i imunosupresivno ili antizapaljensko sredstvo.
16. Ćelija-domaćin, naznačena time, što sadrži: (a) ekspresioni vektor koji uključuje sekvencu nukleinske kiseline koja kodira laki lanac antitela, ili njegovog antigen-vezujućeg fragmenta, iz zahteva 4; i (b) ekspresioni vektor koji uključuje sekvencu nukleinske kiseline koja kodira teški lanac antitela, ili njegovog antigen-vezujućeg fragmenta, iz zahteva 4.
17. Metod proizvodnje vezujućeg jedinjenja naznačen time, što uključuje: kultivisanje ćelije-domaćina iz zahteva 16 u kultivacionom medijumu pod uslovima u kojima se eksprimiraju sekvence nukleinske kiseline, čime se proizvode polipeptidi koji sadrže lake i teške lance antitela, ili njegovog antigen- vezujućeg fragmenta; i sakupljanje antitela, ili njegovog antigen-vezujućeg fragmenta iz ćelije-domaćina ili kultivacionog medijuma.
MEP-2017-73A 2005-08-31 2006-08-29 Inženjerisana anti-il-23 antitela ME02705B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71358505P 2005-08-31 2005-08-31
PCT/US2006/033764 WO2007027714A2 (en) 2005-08-31 2006-08-29 Engineered anti-il-23 antibodies
EP06802592.3A EP1931710B1 (en) 2005-08-31 2006-08-29 Engineered anti-il-23 antibodies

Publications (1)

Publication Number Publication Date
ME02705B true ME02705B (me) 2017-10-20

Family

ID=37685722

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2017-73A ME02705B (me) 2005-08-31 2006-08-29 Inženjerisana anti-il-23 antitela

Country Status (17)

Country Link
US (3) US7807160B2 (me)
EP (3) EP1931710B1 (me)
JP (2) JP5350793B2 (me)
CN (1) CN101296944A (me)
CA (1) CA2620802A1 (me)
CY (2) CY1118760T1 (me)
DK (1) DK1931710T3 (me)
ES (1) ES2619845T3 (me)
HR (1) HRP20170444T1 (me)
HU (2) HUE032131T2 (me)
LT (2) LT1931710T (me)
ME (1) ME02705B (me)
PL (1) PL1931710T3 (me)
PT (1) PT1931710T (me)
RS (1) RS55788B1 (me)
SG (2) SG10201402712QA (me)
WO (1) WO2007027714A2 (me)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2452694B1 (en) * 2005-06-30 2018-11-14 Janssen Biotech, Inc. Anti-IL-23 antibodies, compositions, methods and uses
LT1931710T (lt) 2005-08-31 2017-03-27 Merck Sharp & Dohme Corp. Rekombinantiniai anti-il-23 antikūnai
SI1933869T1 (sl) 2005-09-01 2010-02-26 Schering Corp Uporaba IL-23 in IL-17 antagonistov za zdravljenje avtoimunske očesne vnetne bolezni
AU2006342792A1 (en) * 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
RS55963B1 (sr) 2005-12-29 2017-09-29 Janssen Biotech Inc Humana anti-il-23 antitela, kompozicije, metode i upotrebe
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
WO2007147019A2 (en) * 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
US8414897B1 (en) * 2006-10-02 2013-04-09 The Uab Research Foundation Pathway for Th-17 cell development and methods utilizing same
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
DK2426144T3 (en) 2007-02-23 2019-01-07 Merck Sharp & Dohme Manipulated Anti-IL-23P19 Antibodies
SG178804A1 (en) * 2007-02-23 2012-03-29 Schering Corp Engineered anti-il-23p19 antibodies
NZ579251A (en) 2007-02-28 2012-06-29 Schering Corp Engineered anti-il-23r antibodies
CA2679400A1 (en) * 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
US7981415B2 (en) * 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
US7771720B2 (en) * 2007-09-07 2010-08-10 Cisthera, Inc. Humanized PAI-1 antibodies
US20100203009A1 (en) * 2007-10-02 2010-08-12 The Uab Research Foundation Pathway for Th-17 Cell Development and Methods Utilizing Same
AR068723A1 (es) * 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
AU2009204441B2 (en) 2008-01-09 2015-03-05 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
KR20160116056A (ko) 2008-08-14 2016-10-06 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-ｉｌ-12/ｉｌ-23 항체
EP2331078B1 (en) 2008-08-27 2012-09-19 Merck Sharp & Dohme Corp. Lyophilized formulations of engineered anti-il-23p19 antibodies
JP5564049B2 (ja) * 2008-09-29 2014-07-30 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ１４７抗体、方法及び使用
MX2011006549A (es) 2008-12-19 2011-07-20 Schering Corp Suplemento alimenticio para el cultivo de celula de mamifero y metodos de uso.
WO2010127181A1 (en) 2009-04-29 2010-11-04 Trellis Bioscience, Inc. Improved antibodies immunoreactive with heregulin-coupled her3
US20120269765A1 (en) * 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
JO3244B1 (ar) * 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
SG177025A1 (en) * 2010-06-21 2012-01-30 Agency Science Tech & Res Hepatitis b virus specific antibody and uses thereof
EP4349868A3 (en) * 2010-05-14 2024-08-28 The Board of Trustees of the Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
CA2805653A1 (en) * 2010-07-20 2012-01-26 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
SG190006A1 (en) 2010-11-04 2013-06-28 Boehringer Ingelheim Int Anti-il-23 antibodies
EP2675467A4 (en) * 2011-02-18 2014-06-25 Merck Sharp & Dohme USE OF MDL-1 ANTAGONISTS FOR THE TREATMENT OF SPONDYLARTHROPATHY
EP2583979B1 (en) 2011-10-19 2015-12-16 Effimune Methods to prepare antibodies directed against p19 subunit of human IL-23
EA034778B1 (ru) 2012-02-06 2020-03-19 Инхибркс, Инк. Антитела к cd47 и способы их применения
CN104507497B (zh) 2012-05-03 2018-10-19 勃林格殷格翰国际有限公司 抗IL-23p19抗体
ES2711554T3 (es) 2012-05-22 2019-05-06 Bristol Myers Squibb Co Anticuerpos biespecíficos contra IL-17A/F IL-23 y sus usos
EP2866833B1 (en) 2012-06-27 2019-05-15 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
CA2881966C (en) 2012-08-24 2020-10-06 The Regents Of The University Of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
TWI636063B (zh) * 2013-03-08 2018-09-21 美國禮來大藥廠 結合ｉｌ－２３之抗體
CN105307675A (zh) 2013-03-15 2016-02-03 美国安进公司 使用抗il23抗体治疗克罗恩氏病的方法
CN105209064A (zh) 2013-03-15 2015-12-30 美国安进公司 使用抗il-23抗体治疗银屑病的方法
PT3038650T (pt) 2013-08-30 2021-08-25 Immunogen Inc Anticorpos e ensaios para a deteção do recetor de folato 1
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
AR101753A1 (es) 2014-09-03 2017-01-11 Boehringer Ingelheim Int COMPUESTO DE OBJETIVO A IL-23A Y TNF-a Y USO DEL MISMO
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
SG10202103879YA (en) 2015-02-04 2021-05-28 Boehringer Ingelheim Int Methods of treating inflammatory diseases
JP2018511346A (ja) 2015-03-31 2018-04-26 ブイエイチスクエアード リミテッド ポリペプチド
KR102789821B1 (ko) 2015-03-31 2025-04-02 소리소 파마슈티컬스 인크. 프로테아제-절단가능 링커를 갖는 펩티드 구조물
MX2017013156A (es) 2015-04-14 2018-02-21 Boehringer Ingelheim Int Metodos para tratar enfermedades.
US10576131B2 (en) 2015-06-03 2020-03-03 Affiris Ag IL-23-p19 vaccines
JP6880006B2 (ja) 2015-09-17 2021-06-02 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫複合体を含む治療組み合わせ
HK1258292A1 (zh) 2015-09-17 2019-11-08 Amgen Inc. 使用il23途径生物标志物预测il23拮抗剂的临床应答
TWI733695B (zh) * 2015-09-18 2021-07-21 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
KR20250099459A (ko) * 2015-11-03 2025-07-01 얀센 바이오테크 인코포레이티드 Pd-1과 특이적으로 결합하는 항체 및 그의 용도
AU2016379157A1 (en) 2015-12-22 2018-06-21 Amgen Inc. CCL20 as a predictor of clinical response to IL23-antagonists
EP3974451A3 (en) 2016-04-15 2022-07-06 Boehringer Ingelheim International GmbH Methods of treating inflammatory diseases
EP3474854A4 (en) 2016-06-27 2020-02-19 The Regents of The University of California CANCER TREATMENT COMBINATIONS
US20180105588A1 (en) 2016-10-14 2018-04-19 Boehringer Ingelheim International Gmbh Methods of treating diseases
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
ES3064335T3 (en) 2018-03-05 2026-04-24 Janssen Biotech Inc Methods of treating crohn's disease with anti-il23 specific antibody
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CA3105598A1 (en) 2018-07-13 2020-01-16 Carl GOMMOLL Treating ulcerative colitis with brazikumab
JP7634474B2 (ja) * 2018-07-18 2025-02-21 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子
CN113056482A (zh) 2018-10-18 2021-06-29 默沙东公司 抗rsv抗体的制剂及其使用方法
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
MX2021005905A (es) 2018-11-20 2021-06-23 Janssen Biotech Inc Metodo seguro y eficaz para tratar la psoriasis con el anticuerpo especifico anti-il-23.
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
CN114514243B (zh) 2019-06-21 2025-01-24 索瑞索制药公司 多肽
EP3986570A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Compositions
EP3986571A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
GB201911931D0 (en) * 2019-08-20 2019-10-02 Univ College Cardiff Consultants Ltd Anti-C7 antibody or antibody fragment
TW202123965A (zh) 2019-09-09 2021-07-01 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
EP4077378A1 (en) 2019-12-20 2022-10-26 NovaRock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
US20230073132A1 (en) * 2019-12-31 2023-03-09 Medstar Health, Inc. Anti-cd 160 binding molecules for treating diseases
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
MX2022014430A (es) 2020-05-21 2023-02-22 Janssen Biotech Inc Método para tratar la enfermedad inflamatoria del intestino con una terapia de combinación de anticuerpos para il-23 y tnf alfa.
CN113698480B (zh) * 2021-09-18 2022-07-01 东大生物技术(苏州)有限公司 一组il-23单克隆抗体及其医药用途
TW202323304A (zh) * 2021-09-30 2023-06-16 大陸商江蘇恆瑞醫藥股份有限公司 抗ｉｌ２３抗體融合蛋白及用途
IL324634A (en) 2023-05-15 2026-01-01 Nchroma Bio Inc Compositions and methods for epigenetic regulation of hbv gene expression
WO2026058045A1 (en) 2024-09-12 2026-03-19 Takeda Pharmaceutical Company Limited Alpha4beta7 inhibitor and il-23 inhibitor combination therapy

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0438310A1 (en) 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US5888530A (en) 1995-07-21 1999-03-30 The General Hospital Corporation Method of enhancing delivery of a pharmaceutical formulation
US6060284A (en) * 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
DE69942607D1 (de) 1998-04-14 2010-09-02 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
DE60041393D1 (de) 1999-03-11 2009-03-05 Schering Corp Cytokine aus säugetieren, verwandte reagenzien und verfahren
DE60038304T3 (de) 1999-09-09 2017-04-06 Merck Sharp & Dohme Corp. Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US20070134247A9 (en) 2002-04-12 2007-06-14 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
EP1576011B1 (en) 2002-10-30 2009-08-12 Genentech, Inc. Inhibition of il-17 production
WO2004071517A2 (en) 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
ATE440864T1 (de) * 2003-03-10 2009-09-15 Schering Corp Verwendung von il-23-antagonisten; verwandte reagenzien
JP2007515939A (ja) 2003-05-09 2007-06-21 セントカー・インコーポレーテツド ＩＬ−２３ｐ４０特異的免疫グロブリン由来タンパク質、組成物、方法および用途
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
ES2393555T3 (es) 2003-10-22 2012-12-26 Keck Graduate Institute Métodos para la síntesis de polipéptidos hetero-multiméricos en levaduras usando una estrategia de apareamiento haploide.
AR046833A1 (es) 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
EP1766396B1 (en) 2004-06-07 2010-08-11 Ramot at Tel-Aviv University Ltd. Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
EP2452694B1 (en) * 2005-06-30 2018-11-14 Janssen Biotech, Inc. Anti-IL-23 antibodies, compositions, methods and uses
DE602006015830D1 (de) * 2005-08-25 2010-09-09 Lilly Co Eli Anti-il-23-antikörper
LT1931710T (lt) * 2005-08-31 2017-03-27 Merck Sharp & Dohme Corp. Rekombinantiniai anti-il-23 antikūnai
RS55963B1 (sr) 2005-12-29 2017-09-29 Janssen Biotech Inc Humana anti-il-23 antitela, kompozicije, metode i upotrebe

Also Published As

Publication number Publication date
CN101296944A (zh) 2008-10-29
CY2019041I1 (el) 2020-05-29
US20070048315A1 (en) 2007-03-01
JP5350793B2 (ja) 2013-11-27
SG10201402712QA (en) 2014-08-28
WO2007027714A3 (en) 2007-06-21
DK1931710T3 (en) 2017-04-03
US8362212B2 (en) 2013-01-29
SG165322A1 (en) 2010-10-28
EP3190125A1 (en) 2017-07-12
PL1931710T3 (pl) 2017-06-30
HUE032131T2 (en) 2017-09-28
HRP20170444T1 (hr) 2017-05-19
JP2011130771A (ja) 2011-07-07
EP1931710A2 (en) 2008-06-18
CA2620802A1 (en) 2007-03-08
RS55788B1 (sr) 2017-08-31
LTPA2019520I1 (lt) 2019-11-11
WO2007027714A2 (en) 2007-03-08
US20090156788A1 (en) 2009-06-18
CY2019041I2 (el) 2020-05-29
EP1931710B1 (en) 2017-01-18
PT1931710T (pt) 2017-03-28
CY1118760T1 (el) 2017-07-12
JP2009505677A (ja) 2009-02-12
ES2619845T3 (es) 2017-06-27
HUS1900050I1 (hu) 2019-11-28
LT1931710T (lt) 2017-03-27
US7807160B2 (en) 2010-10-05
US20110002942A1 (en) 2011-01-06
EP2354160A1 (en) 2011-08-10

Similar Documents

Publication Publication Date Title
HRP20170444T1 (hr) Projektirana anti-il-23 antitijela
RU2016119152A (ru) Стабильные и растворимые антитела, ингибирующие vegf
HRP20120611T1 (hr) Anti-il-23p19 antitijela proizvedena genetiäśkim inžinjerstvom
IL302078A (en) Anti-CCR8 monoclonal antibodies and their uses
ES2517420T3 (es) Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
JP2024109678A5 (me)
NZ623347A (en) Novel anti-dr5 antibody
JP2020079252A5 (me)
FI3390451T3 (fi) Kaninisoidut ihmisen vasta-aineet ihmisen ja koiraeläimen il-4r alfaa kohtaan
IL273841B1 (en) Antibodies targeting cd137 and methods of use thereof
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
RU2019118359A (ru) Антитело к cd73 человека
HRP20171690T1 (hr) Antitijela koja se vežu za humani cgrp receptor
PE20061324A1 (es) Anticuerpos anti-il-6, composiciones, metodos y usos
RU2012112829A (ru) Анти-gitr-антитела
RU2016129274A (ru) Канинизированные мышиные антитела к человеческому pd-1
CL2013003140A1 (es) Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene.
JP2018521638A5 (me)
IL296682B1 (en) Method for treating or improving metabolic disorders using gastric inhibitory peptide receptor binding proteins in combination with glucagon-like peptide 1 agonists
NZ603972A (en) Anti-fgfr2 antibodies
HRP20191590T1 (hr) Protutijela za bubrežni antigen 1 i njihov fragment koji veže antigen
PE20090518A1 (es) Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18)
JP2012532851A5 (me)
RU2012103212A (ru) Tlr3 связывающие агенты
AR123480A1 (es) Moléculas de unión terapéuticas